Overview

Bioequivalence Study of Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fasting Conditions

Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of this study was to compare the relative bioavailability of Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets by Ranbaxy Laboratories Limited with that of Monopril ®.-HCT 20-12.5 mg tablets by Bristol-Meyers Squibb following a single oral dose (1 x 20-12.5 mg tablet) in healthy adult subjects under fasting conditions
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Ranbaxy Laboratories Limited
Treatments:
Fosinopril
Hydrochlorothiazide
Criteria
Inclusion Criteria:

1. Subjects should be at least 18 years old

2. Female subjects with negative serum pregnancy test

3. Subject with no clinically significant abnormal lab values at the pre-entry evaluation

4. Subjects with negative or non-reactive urine drug of abuse, hepatitis B, hepatitis C
and HIV screening

5. Subject has acceptable ECG

6. Subject has no evidence of underlying disease at the pre-entry physical examination

7. Subject has agreed to undergo at least a 14 day washout period for prescription drugs
prior to the first dosing of the study and throughout the periods of blood sample
collection

8. Subject has agreed to undergo at least a 7 day washout period for OTC products, herbal
medications, etc. prior to the first dosing of the study medication and throughout the
periods of blood sample collections

9. Subject agrees to abstain from consuming alcohol for at least 48 hours prior to each
dosing and throughout the periods when blood samples are being obtained

10. Subject agrees to abstain from consuming grapefruit, grapefruit juice, or other foods
containing grapefruit for at least 48 hours prior to each dosing and throughout the
periods when blood samples are being obtained

11. Subject has given a written consent to participate

Exclusion Criteria:

1. Subject has a history of chronic alcohol consumption (during past 2 years) or drug
addiction

2. Subject has a history of serious gastrointestinal, renal, hepatic or cardiovascular
disease, tuberculosis, epilepsy, asthma (during past 5 years), diabetes, psychosis or
glaucoma

3. Subject has a history of allergic responses to the class of drug being tested.

4. Subject has donated any blood and/ or plasma within the last thirty (30) days prior to
the first dosing of the study

5. Subject has taken any investigational drug within thirty (30) days prior to the first
dosing of the study

6. Female subjects who are pregnant, breast feeding, or likely to be come pregnant during
the study. Female subjects of child bearing potential must either abstain from sexual
intercourse or use a reliable barrier method (eg condom, IUD) of contraception during
the course of the study (first dosing until the last blood collection)

7. Female subjects who have used implanted or injected hormonal contraceptives (except
Lunelle ® Monthly Injection) anytime during the 6 months prior to study dosing,
Lunelle ® Monthly Injection anytime during the 45 days prior to the study dosing, or
used oral hormonal contraceptives within 14 days before dosing.

8. Subject with the inability to read and/ or sign the consent form